Literature DB >> 9547467

Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.

D Kaufer1, J L Cummings, D Christine.   

Abstract

Neuropsychiatric symptom responses to tacrine were investigated in an open-label study of Alzheimer's outpatients. Forty subjects were stratified into three groups (Mild, Moderate, and Severe) based on Mini-Mental State Examination scores. A significant reduction in total Neuropsychiatric Inventory score across all subjects was principally attributable to changes in the Moderate group. Apathy and disinhibition symptoms were significantly reduced overall. Whereas other symptoms showed differential responses in Mild and Severe subjects, all symptoms improved in Moderate subjects. These findings suggest that disease severity may significantly influence neuropsychiatric symptom responses to tacrine. Putative mechanisms underlying the observed pattern of responses are explored.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547467     DOI: 10.1176/jnp.10.1.55

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  10 in total

Review 1.  Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

Authors:  D I Kaufer
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

4.  Psychosis Due to Neurologic Conditions.

Authors:  David B. Arciniegas; Jeannie L. Topkoff; Kerri Held; Lauren Frey
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

Review 5.  Epidemiology and management of apathy in patients with Alzheimer's disease.

Authors:  Romina Mizrahi; Sergio E Starkstein
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Recognition and Management of Behavioral Disturbances in Dementia.

Authors:  Abhilash K. Desai; George T. Grossberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-06

7.  Role of Cholinesterase Inhibitors in Managing Behavioral Problems in Alzheimer's Disease.

Authors:  Donna L. Masterman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

8.  Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review.

Authors:  Christos G Theleritis; Kostas T Siarkos; Antonios M Politis
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

9.  Self-management and HeAlth Promotion in Early-stage dementia with e-learning for carers (SHAPE): study protocol for a multi-centre randomised controlled trial.

Authors:  Ingelin Testad; Linda Clare; Kaarin Anstey; Geir Selbæk; Guro Hanevold Bjørkløf; Catherine Henderson; Ingvild Dalen; Martha Therese Gjestsen; Shelley Rhodes; Janne Røsvik; Jessica Bollen; Jessica Amos; Martine Marie Kajander; Lynne Quinn; Martin Knapp
Journal:  BMC Public Health       Date:  2020-10-09       Impact factor: 3.295

Review 10.  Pharmacological interventions for apathy in Alzheimer's disease.

Authors:  Myuri T Ruthirakuhan; Nathan Herrmann; Eleenor H Abraham; Sarah Chan; Krista L Lanctôt
Journal:  Cochrane Database Syst Rev       Date:  2018-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.